Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Ph2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo, in Combination With Pembrolizumab, Pemetrexed, and Carboplatin, in 1L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-01)

NCT07098988 is registered in ClinicalTrials.gov with CatalYm GmbH as lead sponsor.

NCT NCT07098988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07098988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Ph2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo, in Combination With Pembrolizumab, Pemetrexed, and Carboplatin, in 1L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-01)
Lead sponsor
CatalYm GmbH
Phase
Phase 2
Overall status
Recruiting
Start date
August 1, 2025
Completion date
March 31, 2031
Enrollment
107 (estimated)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

adult solid tumor, metastatic non-squamous non-small cell lung cancer